CD4 and nasopharyngeal carcinoma: reported that GRb1 combined with apatinib could inhibit tumor cell glycolysis, reduce tumor cell proliferation and migration, upregulate the immune-related indices CD3+ and CD4+, increase apoptosis, enhance the expression of immune regulatory molecules, and exert synergistic anticancer effects on nasopharyngeal carcinoma cells via ginsenosides to inhibit the malignant progression of nasopharyngeal carcinoma (16).